Incidence and Risk Factors of Treatment-Emergent Eczematous Reactions in Patients with Psoriasis Treated with Biologics: A Systematic Review and Meta-Analysis.

What was studied

This was a review of eczema-like skin reactions in people with psoriasis. They took biologic drugs. The team asked how often these reactions occur and what goes with them. They pooled 26 publications with 34,511 exposures. Some studies covered TNF, IL-17, IL-12/23 or IL-23 drugs. 2 studies of deucravacitinib were looked at on their own.

What they found

The pooled rate differed by drug class. IL-17 drugs had the highest rate. IL-23 drugs had the lowest. Within the IL-17 class, secukinumab had a higher rate than ixekizumab. High doses had a higher rate than low doses. Rates were higher in East Asian groups than in Western groups. People with past atopic dermatitis had the strongest link. The hazard ratio was 12.40.

What it means for patients

The team said these reactions go with drug class, dose and study group. They said IL-17 drugs, high doses and East Asian groups had the highest rates.

Why it is not certain yet

A link does not prove cause. Rates differ across drug classes, doses and places. The deucravacitinib studies were few and were looked at separately. Studies and groups differed in many ways.

Source

Incidence and Risk Factors of Treatment-Emergent Eczematous Reactions in Patients with Psoriasis Treated with Biologics: A Systematic Review and Meta-Analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.